Impact of low-dose quetiapine-use on glycosylated hemoglobin, triglyceride and cholesterol levels.

ABSTRACT:

Objective

Quetiapine use at standard doses has been associated with hyperglycemia and dyslipidemia. However, whether even frequently prescribed low-dose quetiapine results in significant metabolic disturbances remains unclear. Thus, this study aimed to investigate the association between off-label, low-dose quetiapine and changes in glycosylated hemoglobin (HbA1c) levels/lipid parameters.

Methods

We identified new users of low-dose quetiapine (≤50 mg tablets) in Denmark 2008-2018 with measurements of HbA1c, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or fasting triglycerides (fTG) within 365 days before and after quetiapine initiation. Mixed-effects linear regression models were used to estimate coefficie

SUBMITTER: Hojlund M 

PROVIDER: S-EPMC10099591 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature